









Markets
/
Stocks
/
nasdaq-lab
/

Standard BioTools Inc

LAB

1.410USD

+0.060+4.44%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

538.19MMarket Cap

LossP/E TTM



Standard BioTools Inc

1.410

+0.060+4.44%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

76 / 207

Overall Ranking

198 / 4721

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

1.775

Target Price

+31.48%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. The Company's segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The Company provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company also provides differentiated multi-omics tools for research.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 78.09% year-on-year.

Undervalued

The company’s latest PE is -4.57, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 283.64M shares, decreasing 9.05% quarter-over-quarter.

Held by Andreas Halvorsen

Star Investor Andreas Halvorsen holds 58.65M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.65.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 6.32, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 21.76M, representing a year-over-year decrease of 41.51%, while its net profit experienced a year-over-year decrease of 26.81%.

Score

Industry at a Glance

Previous score

6.32

Change



Financials

8.77

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.79

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

3.64

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.33

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 1.20, which is lower than the Healthcare Equipment & Supplies industry's average of 2.00. Its current P/E ratio is -4.38, which is -54.32% below the recent high of -2.00 and 37.99% above the recent low of -2.71.

Score

Industry at a Glance

Previous score

1.20

Change

1.6

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 76/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 7.33, which is lower than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Standard BioTools Inc is 1.77, with a high of 2.00 and a low of 1.55.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

1.775

Target Price

+31.48%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Standard BioTools Inc

LAB

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 7.04, which is higher than the Healthcare Equipment & Supplies industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 1.45 and the support level at 1.22, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.04

Change

1.63

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.024

Buy

RSI(14)

60.583

Neutral

STOCH(KDJ)(9,3,3)

80.647

Buy

ATR(14)

0.078

High Vlolatility

CCI(14)

139.791

Buy

Williams %R

4.545

Overbought

TRIX(12,20)

0.197

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

1.360

Buy

MA10

1.335

Buy

MA20

1.300

Buy

MA50

1.305

Buy

MA100

1.213

Buy

MA200

1.341

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 7.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 74.68%, representing a quarter-over-quarter decrease of 1.22%. The largest institutional shareholder is Andreas Halvorsen, holding a total of 58.65M shares, representing 15.35% of shares outstanding, with 2.55% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Casdin Capital, LLC

76.08M

Viking Global Investors LP

Star Investors

58.65M

BlackRock Institutional Trust Company, N.A.

22.35M

-1.46%

The Vanguard Group, Inc.

Star Investors

17.17M

+0.40%

Long Focus Capital Management LLC

6.70M

Geode Capital Management, L.L.C.

7.21M

+3.30%

State Street Global Advisors (US)

6.36M

+1.10%

Amova Asset Management Co., Ltd.

6.23M

-5.81%

Hollow Brook Wealth Management, LLC

5.55M

+0.91%

MAK Capital One, LLC

2.77M

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.17, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.31. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.